Press Releases

Date Title
November 6, 2018
Oncobiologics Advances ONS-5010 into wet AMD Clinical Trial
Receives commitment for $20 million in proceeds from equity private placement Restructures and extends maturity on $13.5 million of outstanding senior secured notes CRANBURY, N.J. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that it has begun dosing patients
August 14, 2018
Oncobiologics Provides Business Update and Reports Third Quarter Financial Results for Fiscal 2018

CRANBURY, N.J. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ: ONS) today reported financial results and business highlights for its three and nine months ended June 30, 2018 . Recent Highlights: Continued to prepare ONS-5010 for clinical trials Converted majority of Series A

August 2, 2018
Oncobiologics Appoints Lawrence A. Kenyon as President and CEO

CRANBURY, N.J. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that Lawrence A. Kenyon , its Chief Financial Officer (CFO) and Corporate Secretary, has been appointed to the role of President and Chief Executive Officer (CEO), and has joined the Company’s Board

July 19, 2018
Oncobiologics Completes Exchange of Series A Convertible Preferred Stock for Newly Created Series A-1 Convertible Preferred Stock
CRANBURY, N.J. , July 19, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (Nasdaq:ONS) today announced that, on July 18, 2018 , the Company completed the exchange of an aggregate of 58,735 shares of voting Series A Convertible Preferred Stock (the “Series A”) held by GMS Tenshi Holdings Pte.
July 11, 2018
Oncobiologics Regains Compliance with Applicable Nasdaq Listing Requirements
CRANBURY, N.J. , July 11, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (Nasdaq:ONS) today announced that, on July 10, 2018 , the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with the applicable requirements for the continued listing of
June 20, 2018
Oncobiologics Announces Conversion of Majority of Series A Convertible Preferred Stock
CRANBURY, N.J. , June 20, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) (the “Company”) today announced that GMS Tenshi Holdings Pte. Limited (“GMS Tenshi”), the Company’s strategic business partner and largest investor, has converted 80% of its Series A convertible preferred stock
June 18, 2018
Oncobiologics Announces Randy Thurman as Executive Chairman of the Board of Directors and Lawrence A. Kenyon as Interim CEO
CRANBURY, N.J. , June 18, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that Pankaj Mohan , Ph.D., its Chairman and Chief Executive Officer (CEO), has stepped down as CEO and Chairman of the board with immediate effect. Dr. Mohan will remain a member of Oncobiologics’
June 13, 2018
Oncobiologics Enters into First CDMO Contract
CRANBURY, N.J. , June 13, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that it has entered into a Master Services Agreement (MSA) with Sonnet BioTherapeutics, Inc. , a privately held development stage biopharmaceutical company, and has officially launched its
June 8, 2018
Oncobiologics Closes Second Tranche of $15 Million Private Placement
CRANBURY, N.J. , June 08, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) (the “Company”) today announced that it has closed on the second, and final, tranche of a $15.0 million private placement of shares of its common stock and warrants that have an aggregate exercise price of
June 4, 2018
Stelis Biopharma and Oncobiologics to Unveil Bio2Source CDMO Offering at BIO 2018
CRANBURY, N.J. , June 04, 2018 (GLOBE NEWSWIRE) -- Stelis Biopharma and Oncobiologics, Inc. (NASDAQ:ONS) today announced that they will unveil a new contract development and manufacturing (“CDMO”) effort at BIO 2018 in Boston.  Marketed under the name, Bio2Source, Oncobiologics and Stelis Biopharma
Displaying 1 - 10 of 47